Myo-inositol

Inositol (Myo-inositol) is indicated in adults for the treatment of:

• Polycystic ovary syndrome (PCOS)
• Anovulation
• Menstrual disorders such as amenorrhea
• Hyperandrogenism complaints such as hirsutism, alopecia, acanthosis nigricans, acne
• Ovarian hyperthecosis
• Insulin resistance
• Male infertility

Each film Coated tablet contains Inositol (Myo-inositol) USP 750 mg.

Inositols are important molecules in promoting female fertility and in sustaining physiological pregnancy. Myo-inositol, a major form of Inositol, has an established role in human physiology. Myo-inositol represents the most abundant inositol isomer in humans, and it is commonly found in almost every tissue, particularly in brain, blood, fat, kidney, lung, ovaries, and testes, where it participates in several cellular pathways,

Inositol (Myo-inositol) as second messenger of gonadotropins and insulin, it guarantees the correct development of oocytes and the progression of embryogenesis. Available evidence demonstrates that the supplementation with Inositol (Myo-inositol) enhances the probability of achieving pregnancy and reduces the onset of adverse maternal effects and neonatal outcomes. Specifically, in the pursuit of pregnancy, Inositol (Myo-inositol) proved to induce ovulation and restore the physiological menstrual cycle in infertile women, particularly in those with Polycystic ovary syndrome (PCOS). Moreover, Inositol (Myo-inositol) supplementation is also useful for women undergoing Assisted reproductive technology (ART), improving oocyte and embryo quality. During pregnancy, Inositol (Myo-inositol) reduces the risk of altered metabolic conditions like Gestational Diabetes Mellitus (GDM), which may lead to miscarriages or stillborn babies. In addition, Inositol (Myo-inositol) seems to reduce the risk of Neural tube defects (NTDs) in folate-resistant women.

Recommended dosage for lipid-lowering and improving conditions related to peripheral vascular insufficiency ranges from 1500 mg to 4000 mg daily, in divided dosages of two to three times daily with or without food for at least 3 months.

Use in children and adolescents: There is a lack of long-term safety data to support the safe use of Inositol (Myo-inositol) in children and adolescents.

Concomitant use of anti-diabetic drug and Inositol (Myo-inositol) may result in more reduced blood glucose than only anti-diabetic drug therapy

Patients with a known hypersensitivity to any component of this product.

Common: Well tolerated in recommended dose. Only mild gastrointestinal side effects can be shown with higher doses.

Inositol is possibly safe when taken by mouth during pregnancy. There isn't enough reliable information to know if Inositol (Myo-inositol) is safe to use when breast-feeding.

Patient with diabetes should be cautious about use of this medication.

Generally, Inositol (Myo-inositol) seems to be safe and relatively well tolerated in recommended dose.

Nicotinic acid group, Oral nutritional preparations

Store in a cool and dry place, away from light & moisture. Keep all medicines out of reach of children.